Physician profile
Lisa R Hackney
NPI 1821250291
$726.54
in general payments reported to CMS, 2019-2025
16 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.56 · 2020: $58.11 · 2021: $101 · 2022: $111 · 2023: $163 · 2024: $86.00 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $113.82 | 2020-2024 | |
| Csl Behring | $108.54 | 2019-2025 | Hemgenix |
| Bayer Healthcare Pharmaceuticals INC. | $62.77 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $62.25 | 2019-2024 | Ultomiris |
| Novo Nordisk INC | $50.33 | 2021-2025 | Alhemo |
| Chiesi USA, INC. | $47.01 | 2022-2025 | Ferriprox |
| Genzyme Corporation | $43.06 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $40.04 | 2025 | Prevymis |
| Adaptive Biotechnologies Corporation | $34.58 | 2020-2021 | |
| Global Blood Therapeutics, INC. | $34.50 | 2021-2022 | |
| Genentech USA, INC. | $33.86 | 2025 | Hemlibra |
| Amgen INC. | $30.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.06 | 2023 | Vonvendi |
| Aurobindo Pharma USA, INC. | $18.47 | 2020 | |
| Bioverativ Therapeutics INC. | $18.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hackney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.